Beni Rovinski, Ph.D.

Managing Director

Current board roles

Antios Therapeutics
Antiva Biosciences
Bright Angel Therapeutics

Previous board roles

Aegera Pharmaceuticals
Aurinia Pharmaceuticals
Avalon Pharmaceuticals
Cervelo Pharmaceuticals
G1 Therapeutics
Health Hero Network
Inovise Medical, Inc.
KAI Pharmaceuticals
SGX Pharmaceuticals
Vascular Pharmaceuticals


PhD (biochemistry) McGill University Montréal, Québec
BSc (biochemistry) Rice University, Houston, Texas
Post-doctoral studies in molecular oncology and retrovirology, Ontario Cancer Institute, Toronto, Ontario

Industry affiliations

American Association for the Advancement of Science
Canadian Association of Alternative Strategies & Assets (CAASA)
Canadian Association for HIV Researchers (CAHR)
Center for Commercialization of Regenerative Medicine (CCRM)
Government of Canada COVID-19 Vaccine Task Force
Life Sciences Ontario - Director
National Venture Capital Association (NVCA)
Ontario Genomics - Director
Rice University Alliance for Technology and Entrepreneurship
The American Society for Microbiology

With over 30 years of investment, operational, managerial and research experience in the healthcare industry, Beni has helped build life sciences companies at all stages of development. Known both as a senior scientist and as an achievement-oriented executive, with demonstrated success in strategic planning, drug development, and operational management of global multifunctional teams, Beni has established a sound reputation built on his clarity of objectives, leadership, judgement and integrity.

Beni’s investment focus is primarily on North American mid- to late-stage private and public companies involved in drug discovery and development, biological and small molecule therapeutics, drug delivery, specialty pharmaceuticals, genomics, proteomics and diagnostic devices.

With a proven track record of delivering results both as a senior scientist and a business executive, Beni has held several senior management positions in the biotechnology sector, including 13 years at Sanofi Pasteur (formerly Aventis Pasteur) where he was a senior scientist and director of molecular virology, with a particular focus in the areas of virology, vaccine development, recombinant protein production, and functional genomics. While at Aventis, Beni led global research and development programs in the areas of HIV/AIDS and therapeutic cancer vaccines (e.g., colorectal, prostate and cervical cancers), bringing several of them through to clinical stage.

Beni is fluent in English, French and Spanish. He has published over 25 scientific articles and reviews and is the recipient of 32 issued patents.